Dealmaking Shifts for Cell and Gene Therapies

Dealmaking shifts for cell and gene therapies

Deals and funding for cell and gene therapies have declined from recent highs, but emerging technologies and new applications may drive a rebound, supported by data from the DealForma database. Read the article here

All of this by stage, disease indication, modality, target…

+ 0 k
Licensing Deals
+ 0 k
M&A
+ 0 k
Other Deals
+ 0 k
Funding Rounds
+ 0 k
Company Profiles
+ 0 k
Drug Sales Figures